CA2947736C - Vmat2 inhibitors for the treatment of hyperkinetic movement disorders - Google Patents

Vmat2 inhibitors for the treatment of hyperkinetic movement disorders Download PDF

Info

Publication number
CA2947736C
CA2947736C CA2947736A CA2947736A CA2947736C CA 2947736 C CA2947736 C CA 2947736C CA 2947736 A CA2947736 A CA 2947736A CA 2947736 A CA2947736 A CA 2947736A CA 2947736 C CA2947736 C CA 2947736C
Authority
CA
Canada
Prior art keywords
dimethoxy
htbz
hexahydro
ester
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2947736A
Other languages
English (en)
French (fr)
Other versions
CA2947736A1 (en
Inventor
Christopher F. O'Brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CA2947736A1 publication Critical patent/CA2947736A1/en
Application granted granted Critical
Publication of CA2947736C publication Critical patent/CA2947736C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2947736A 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders Active CA2947736C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
US61/989,240 2014-05-06
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Publications (2)

Publication Number Publication Date
CA2947736A1 CA2947736A1 (en) 2015-11-12
CA2947736C true CA2947736C (en) 2023-04-18

Family

ID=53264772

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2947736A Active CA2947736C (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Country Status (24)

Country Link
US (3) US20170071932A1 (enExample)
EP (3) EP4389227A3 (enExample)
JP (4) JP6635945B2 (enExample)
KR (5) KR20220140647A (enExample)
CN (3) CN112741835A (enExample)
AU (1) AU2015256012B2 (enExample)
CA (1) CA2947736C (enExample)
CY (1) CY1125058T1 (enExample)
DK (2) DK3139925T3 (enExample)
ES (2) ES2904526T3 (enExample)
FI (1) FI3936130T3 (enExample)
HR (2) HRP20220025T1 (enExample)
HU (2) HUE066361T2 (enExample)
IL (1) IL248745B (enExample)
LT (2) LT3139925T (enExample)
MX (1) MX387625B (enExample)
NZ (1) NZ725826A (enExample)
PL (2) PL3139925T3 (enExample)
PT (2) PT3139925T (enExample)
RS (2) RS65359B1 (enExample)
RU (1) RU2753740C2 (enExample)
SI (2) SI3936130T1 (enExample)
SM (2) SMT202400199T1 (enExample)
WO (1) WO2015171802A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3875459T (lt) * 2015-10-30 2024-02-26 Neurocrine Biosciences, Inc. Valbenazino dihidrochlorido druskos ir jų polimorfai
CA3009169A1 (en) * 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
EP3473623B1 (en) 2016-06-29 2020-07-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of nbi-98854, preparation method therefor and use thereof
JP2020500875A (ja) * 2016-12-02 2020-01-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
US10703750B2 (en) 2017-01-10 2020-07-07 Sandoz Ag Crystalline valbenazine free base
JP7090151B2 (ja) 2017-01-27 2022-06-23 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
US10954235B2 (en) 2017-02-27 2021-03-23 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
JP2020512986A (ja) * 2017-04-01 2020-04-30 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療に使用するための（＋）−α−ジヒドロテトラベナジン
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
CN110691596A (zh) * 2017-04-01 2020-01-14 阿德普蒂奥制药有限公司 药物组合物
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
MA50175B1 (fr) 2017-09-21 2025-05-30 Neurocrine Biosciences, Inc. Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc Methods for the administration of certain VMAT2 inhibitors
WO2019094491A1 (en) * 2017-11-08 2019-05-16 Yuhua Li Esters of dihydrotetrabenazine
CA3086611C (en) 2017-12-26 2023-07-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
CA3097189A1 (en) * 2018-04-25 2019-10-31 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
WO2019241555A1 (en) 2018-06-14 2019-12-19 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2020070236A1 (en) 2018-10-04 2020-04-09 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
JOP20210274A1 (ar) * 2019-05-09 2023-01-30 Neurocrine Biosciences Inc طرق لإعطاء مثبط vmat2 معين
US10940141B1 (en) * 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007317242B2 (en) 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
JP2010509336A (ja) * 2006-11-09 2010-03-25 ニューヨーク ユニバーシティ サンドイッチ材料の製造方法、ガラス／セラミック／ガラス複合構造物、ガラス／セラミック／ガラス、医科あるいは歯科補綴、およびガラス／ジルコニア／ガラスサンドイッチ材料
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
EP3345905B1 (en) 2008-09-18 2021-09-01 Auspex Pharmaceuticals, Inc. Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
CA2771539A1 (en) * 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
JP6362601B2 (ja) * 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
CN106061506A (zh) * 2014-02-07 2016-10-26 纽罗克里生物科学有限公司 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途

Also Published As

Publication number Publication date
AU2015256012A1 (en) 2016-11-24
IL248745A0 (en) 2017-01-31
HUE066361T2 (hu) 2024-07-28
CA2947736A1 (en) 2015-11-12
ES2904526T3 (es) 2022-04-05
MX387625B (es) 2025-03-18
CN106456629A (zh) 2017-02-22
JP2017514850A (ja) 2017-06-08
KR20200133003A (ko) 2020-11-25
PT3139925T (pt) 2022-01-26
EP4389227A2 (en) 2024-06-26
LT3936130T (lt) 2024-04-25
KR20220140647A (ko) 2022-10-18
RU2016147523A3 (enExample) 2018-12-28
LT3139925T (lt) 2022-01-25
SMT202400199T1 (it) 2024-07-09
HUE057839T2 (hu) 2022-06-28
IL248745B (en) 2022-07-01
SI3936130T1 (sl) 2024-05-31
SI3139925T1 (sl) 2022-04-29
DK3139925T3 (da) 2021-12-20
JP2019218407A (ja) 2019-12-26
EP3139925B1 (en) 2021-12-01
HRP20220025T1 (hr) 2022-04-01
EP3936130A1 (en) 2022-01-12
EP3936130B1 (en) 2024-02-14
WO2015171802A1 (en) 2015-11-12
HRP20240459T1 (hr) 2024-06-21
JP6635945B2 (ja) 2020-01-29
SMT202200193T1 (it) 2022-07-21
US20200101063A1 (en) 2020-04-02
CY1125058T1 (el) 2023-06-09
RU2753740C2 (ru) 2021-08-23
US20170071932A1 (en) 2017-03-16
CN112741836A (zh) 2021-05-04
CN112741835A (zh) 2021-05-04
US20210196702A1 (en) 2021-07-01
JP2024153782A (ja) 2024-10-29
PL3936130T3 (pl) 2024-06-10
DK3936130T3 (da) 2024-03-25
JP2021191799A (ja) 2021-12-16
RS65359B1 (sr) 2024-04-30
EP3139925A1 (en) 2017-03-15
ES2976207T3 (es) 2024-07-26
KR20240011255A (ko) 2024-01-25
MX2016014429A (es) 2017-04-06
AU2015256012B2 (en) 2020-07-23
PL3139925T3 (pl) 2022-03-21
NZ725826A (en) 2023-05-26
PT3936130T (pt) 2024-04-17
EP4389227A3 (en) 2024-09-04
FI3936130T3 (fi) 2024-04-23
RU2016147523A (ru) 2018-06-08
KR20160147044A (ko) 2016-12-21
RS62782B1 (sr) 2022-01-31
KR20250029267A (ko) 2025-03-04

Similar Documents

Publication Publication Date Title
CA2947736C (en) Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
US20080255079A1 (en) Therapeutic Use of Nefopam and Analogues Thereof
HK40111840A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK40067005A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK40067005B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303A1 (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
EP3664787B1 (en) Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors
WO2022060978A1 (en) Methods of treating parkinson's disease and related disorders with pde10a inhibitors
US20080070952A1 (en) Inhibition or Treatment of Dyskinesia
EP2255807A1 (en) Method of treating sleep disorders using the combination of eplivanserin and zolpidem

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200428

EEER Examination request

Effective date: 20200428

EEER Examination request

Effective date: 20200428

EEER Examination request

Effective date: 20200428

EEER Examination request

Effective date: 20200428